BRPI0714803B8 - compostos peptidomiméticos de smac, seus usos, e composição farmacêutica - Google Patents

compostos peptidomiméticos de smac, seus usos, e composição farmacêutica

Info

Publication number
BRPI0714803B8
BRPI0714803B8 BRPI0714803A BRPI0714803A BRPI0714803B8 BR PI0714803 B8 BRPI0714803 B8 BR PI0714803B8 BR PI0714803 A BRPI0714803 A BR PI0714803A BR PI0714803 A BRPI0714803 A BR PI0714803A BR PI0714803 B8 BRPI0714803 B8 BR PI0714803B8
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
peptidomimetic compounds
compounds
smac peptidomimetic
smac
Prior art date
Application number
BRPI0714803A
Other languages
English (en)
Inventor
Hiu-Tung Chen Christine
Sean Straub Christopher
He Feng
Yang Fan
Lei Huangshu
Luu Pham Ly
Zawel Leigh
G Charest Mark
Dai Miao
David Wang Run-Ming
Kumar Sharma Sushil
Chen Zhuoliang
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38686647&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0714803(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0714803A2 publication Critical patent/BRPI0714803A2/pt
Publication of BRPI0714803B1 publication Critical patent/BRPI0714803B1/pt
Publication of BRPI0714803B8 publication Critical patent/BRPI0714803B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

compostos peptidomiméticos de smac, uso dos mesmos e composição farmacêutica compreendendo os ditos compostos. a presente invenção refere-se a um composto da fórmula: (i) ou sais farmaceuticamente aceitáveis dos mesmos, e uso desses compostos para o tratamento de doenças proliferativas como, por exemplo câncer, em mamíferos.
BRPI0714803A 2006-08-02 2007-07-31 compostos peptidomiméticos de smac, seus usos, e composição farmacêutica BRPI0714803B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US83500006P 2006-08-02 2006-08-02
US60/835,000 2006-08-02
PCT/US2007/074790 WO2008016893A1 (en) 2006-08-02 2007-07-31 Smac peptidomimetics useful as iap inhibitors

Publications (3)

Publication Number Publication Date
BRPI0714803A2 BRPI0714803A2 (pt) 2013-05-21
BRPI0714803B1 BRPI0714803B1 (pt) 2021-03-09
BRPI0714803B8 true BRPI0714803B8 (pt) 2021-05-25

Family

ID=38686647

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0714803A BRPI0714803B8 (pt) 2006-08-02 2007-07-31 compostos peptidomiméticos de smac, seus usos, e composição farmacêutica

Country Status (42)

Country Link
US (3) US8552003B2 (pt)
EP (3) EP2051990B1 (pt)
JP (1) JP4875749B2 (pt)
KR (2) KR101087878B1 (pt)
CN (2) CN101511860B (pt)
AR (3) AR062159A1 (pt)
AU (1) AU2007281230B2 (pt)
BR (1) BRPI0714803B8 (pt)
CA (1) CA2658525C (pt)
CL (1) CL2007002234A1 (pt)
CR (2) CR10567A (pt)
CU (2) CU23866B1 (pt)
DK (1) DK2051990T3 (pt)
DO (1) DOP2013000084A (pt)
EA (2) EA201401247A1 (pt)
ES (2) ES2405947T3 (pt)
GE (1) GEP20115251B (pt)
GT (2) GT200900019A (pt)
HK (2) HK1176613A1 (pt)
HN (1) HN2009000214A (pt)
HR (1) HRP20130373T1 (pt)
IL (3) IL196596A (pt)
JO (1) JO2848B1 (pt)
MA (1) MA30652B1 (pt)
ME (1) ME00585A (pt)
MX (1) MX2009001212A (pt)
MY (1) MY150460A (pt)
NI (2) NI200900081A (pt)
NO (1) NO342230B1 (pt)
NZ (1) NZ574393A (pt)
PA (1) PA8740901A1 (pt)
PE (5) PE20110218A1 (pt)
PL (1) PL2051990T3 (pt)
PT (1) PT2051990E (pt)
SI (1) SI2051990T1 (pt)
SM (1) SMP200900013B (pt)
SV (1) SV2009003160A (pt)
TN (1) TN2009000034A1 (pt)
TW (1) TWI408133B (pt)
UA (1) UA95485C2 (pt)
WO (1) WO2008016893A1 (pt)
ZA (1) ZA200900371B (pt)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ME02125B (me) 2004-04-07 2013-04-30 Novartis Ag Inhibitori protein apoptoze (iap)
ES2475207T3 (es) 2004-07-15 2014-07-10 Tetralogic Pharmaceuticals Corporation Compuestos de unión a IAP
EA019420B1 (ru) 2004-12-20 2014-03-31 Дженентех, Инк. Пирролидиновые ингибиторы иап (ингибиторов апоптоза)
BRPI0607988A2 (pt) 2005-02-25 2009-10-27 Tetralogic Pharmaceuticals composto, composição farmacêutica, e método para induzir apoptose em uma célula
US7772177B2 (en) 2005-05-18 2010-08-10 Aegera Therapeutics, Inc. BIR domain binding compounds
JP2009512719A (ja) 2005-10-25 2009-03-26 アエゲラ セラピューティクス インコーポレイテッド Ｉａｐｂｉｒドメイン結合化合物
TWI543988B (zh) 2006-03-16 2016-08-01 科學製藥股份有限公司 結合於細胞凋亡抑制蛋白（ｉａｐ）之桿狀病毒ｉａｐ重複序列（ｂｉｒ）區域之化合物
MY159563A (en) 2006-05-16 2017-01-13 Pharmascience Inc Iap bir domain binding compounds
US20100056495A1 (en) * 2006-07-24 2010-03-04 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
CL2007002166A1 (es) 2006-07-24 2008-01-25 Tetralogic Pharm Corp Compuestos derivados de heterociclos de nitrogeno, antagonistas de los inhibidores de las proteinas de la apoptosis; sus composiciones farmaceuticas; y uso de dichos compuestos para el tratamiento del cancer.
WO2008014263A2 (en) 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Dimeric iap antagonists
EP2076778A2 (en) * 2006-10-19 2009-07-08 Novartis AG Organic compounds
EP2089027A1 (en) * 2006-11-28 2009-08-19 Novartis AG Use of iap inhibitors for the treatment of acute myeloid leukemia
CA2670498A1 (en) * 2006-11-28 2008-06-05 Novartis Ag Combination of iap inhibitors and flt3 inhibitors
AU2007337104A1 (en) * 2006-12-19 2008-07-03 Genentech, Inc. Imidazopyridine inhibitors of IAP
AR066348A1 (es) 2007-04-30 2009-08-12 Genentech Inc Inhibidores de las iap
US9750729B2 (en) * 2008-05-16 2017-09-05 Dana-Farber Cancer Institute, Inc. Immunomodulation by IAP inhibitors
NZ590550A (en) 2008-08-02 2013-05-31 Genentech Inc Inhibitors of Apoptosis (IAP) for treating cancer
US8841067B2 (en) 2009-01-09 2014-09-23 Dana-Farber Cancer Institute, Inc. NOL3 is a predictor of patient outcome
US8283372B2 (en) 2009-07-02 2012-10-09 Tetralogic Pharmaceuticals Corp. 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic
US20110034469A1 (en) 2009-08-04 2011-02-10 Takeda Pharmaceutical Company Limited Heterocyclic Compound
US20120129895A1 (en) * 2009-08-11 2012-05-24 Colleen Conway Methods of treatment
BR112012003118A2 (pt) * 2009-08-12 2016-02-23 Novartis Ag formulações orais sólidas e formas cristalinas de um inibidor de proteína apoptose
RU2567544C2 (ru) 2010-02-12 2015-11-10 Фармасайенс Инк. Bir домен iap связывающие соединения
UY33236A (es) 2010-02-25 2011-09-30 Novartis Ag Inhibidores dimericos de las iap
DK2611797T3 (en) 2010-08-31 2017-02-13 Hanmi Science Co Ltd QUINOLINE OR QUINAZOLINE DERIVATIVES WITH APOPTOSE-INducing ACTIVITY ON CELLS
WO2012052758A1 (en) 2010-10-22 2012-04-26 Astrazeneca Ab Response biomarkers for iap antagonists in human cancers
UY33794A (es) 2010-12-13 2012-07-31 Novartis Ag Inhibidores diméricos de las iap
US9181266B2 (en) 2011-07-13 2015-11-10 Novartis Ag 2-piperidin-1-yl-acetamide compounds for use as tankyrase inhibitors
WO2013010092A1 (en) 2011-07-13 2013-01-17 Novartis Ag 4-oxo-3,5,7,8-tetrahydro-4h-pyrano {4,3-d} pyrminidinyl compounds for use as tankyrase inhibitors
US20140243276A1 (en) 2011-09-30 2014-08-28 Tetralogic Pharmaceuticals Corporation Smac mimetic (birinapant) for use in the treatment of proliferative diseases (cancer)
US8859541B2 (en) * 2012-02-27 2014-10-14 Boehringer Ingelheim International Gmbh 6-alkynylpyridines
KR20150023445A (ko) * 2012-05-22 2015-03-05 에프. 호프만-라 로슈 아게 치환된 다이피리딜아민 및 이의 용도
KR20140011773A (ko) * 2012-07-19 2014-01-29 한미약품 주식회사 이중 저해 활성을 갖는 헤테로고리 유도체
CN105164114B (zh) 2013-05-01 2018-03-23 豪夫迈·罗氏有限公司 C‑连接的杂环烷基取代的嘧啶类和它们的用途
JP6785653B2 (ja) 2013-06-25 2020-11-18 ザ・ウォルター・アンド・エリザ・ホール・インスティテュート・オブ・メディカル・リサーチ 細胞内感染の処置方法
US10570204B2 (en) 2013-09-26 2020-02-25 The Medical College Of Wisconsin, Inc. Methods for treating hematologic cancers
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
EP3116909B1 (en) 2014-03-14 2019-11-13 Novartis Ag Antibody molecules to lag-3 and uses thereof
EP3925622A1 (en) 2014-09-13 2021-12-22 Novartis AG Combination therapies
CA2963281A1 (en) 2014-10-03 2016-04-07 Novartis Ag Combination therapies
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
EP4245376A3 (en) 2014-10-14 2023-12-13 Novartis AG Antibody molecules to pd-l1 and uses thereof
WO2016079527A1 (en) 2014-11-19 2016-05-26 Tetralogic Birinapant Uk Ltd Combination therapy
WO2016097773A1 (en) 2014-12-19 2016-06-23 Children's Cancer Institute Therapeutic iap antagonists for treating proliferative disorders
JO3746B1 (ar) 2015-03-10 2021-01-31 Aduro Biotech Inc تركيبات وطرق لتنشيط الإشارات المعتمدة على "منبه أو تحفيز جين انترفيرون"
GB201506871D0 (en) 2015-04-22 2015-06-03 Glaxosmithkline Ip Dev Ltd Novel compounds
US20180207273A1 (en) 2015-07-29 2018-07-26 Novartis Ag Combination therapies comprising antibody molecules to tim-3
LT3317301T (lt) 2015-07-29 2021-07-26 Novartis Ag Kombinuotos terapijos, apimančios antikūno molekules prieš lag-3
EP3328418A1 (en) 2015-07-29 2018-06-06 Novartis AG Combination therapies comprising antibody molecules to pd-1
MA43186B1 (fr) 2015-11-03 2022-03-31 Janssen Biotech Inc Anticorps se liant spécifiquement à pd-1 et leurs utilisations
MX2018007423A (es) 2015-12-17 2018-11-09 Novartis Ag Moleculas de anticuerpo que se unen a pd-1 y usos de las mismas.
JP2019514878A (ja) 2016-04-20 2019-06-06 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ Ｒｉｐｋ２阻害剤を含むコンジュゲート
GB201610147D0 (en) 2016-06-10 2016-07-27 Glaxosmithkline Ip Dev Ltd Novel compounds
EP3507367A4 (en) 2016-07-05 2020-03-25 Aduro BioTech, Inc. CYCLIC DINUCLEOTID COMPOUNDS WITH INCLUDED NUCLEIC ACIDS AND USES THEREOF
CN106496213B (zh) * 2016-09-30 2019-08-20 东南大学 Lcl161前药及其制备方法和应用
JP6899993B2 (ja) * 2016-10-04 2021-07-07 国立医薬品食品衛生研究所長 複素環化合物
US20200046684A1 (en) 2017-03-31 2020-02-13 Boehringer Ingelheim International Gmbh Anticancer combination therapy
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
PE20200717A1 (es) 2017-06-22 2020-07-21 Novartis Ag Moleculas de anticuerpo que se unen a cd73 y usos de las mismas
EP3642240A1 (en) 2017-06-22 2020-04-29 Novartis AG Antibody molecules to cd73 and uses thereof
MX2020004756A (es) 2017-11-16 2020-08-20 Novartis Ag Terapias de combinacion.
CN108484640B (zh) * 2018-05-22 2020-09-15 南京华威医药科技集团有限公司 一种抗肿瘤的细胞凋亡蛋白抑制剂
TW202015726A (zh) 2018-05-30 2020-05-01 瑞士商諾華公司 Ｅｎｔｐｄ２抗體、組合療法、及使用該等抗體和組合療法之方法
US20210214459A1 (en) 2018-05-31 2021-07-15 Novartis Ag Antibody molecules to cd73 and uses thereof
TW202016151A (zh) 2018-06-09 2020-05-01 德商百靈佳殷格翰國際股份有限公司 針對癌症治療之多特異性結合蛋白
US11639354B2 (en) 2018-07-31 2023-05-02 Fimecs, Inc. Heterocyclic compound
US20220096436A1 (en) 2019-01-17 2022-03-31 Debiopharm International S.A. Combination product for the treatment of cancer
TW202043466A (zh) 2019-01-25 2020-12-01 德商百靈佳殷格翰國際股份有限公司 編碼ccl21之重組棒狀病毒
WO2020206137A1 (en) 2019-04-04 2020-10-08 Dana-Farber Cancer Institute, Inc. Cdk2/5 degraders and uses thereof
TW202100184A (zh) 2019-05-20 2021-01-01 瑞士商諾華公司 Mcl-1抑制劑抗體－藥物結合物及使用方法
US20220402935A1 (en) 2019-07-31 2022-12-22 Fimecs, Inc. Heterocyclic compound
CN114502590A (zh) 2019-09-18 2022-05-13 诺华股份有限公司 Entpd2抗体、组合疗法、以及使用这些抗体和组合疗法的方法
CA3151770A1 (en) 2019-09-25 2021-04-01 Silvano BRIENZA Dosing regimens for treatment of patients with locally advanced squamous cell carcinoma
KR20220130190A (ko) 2020-01-20 2022-09-26 아스트라제네카 아베 암 치료를 위한 표피성장인자 수용체 티로신 키나제 억제제
PE20231293A1 (es) 2020-06-03 2023-08-22 Boehringer Ingelheim Int Rhabdovirus recombinante que codifica una proteina de fusion fc de dominio extracelular cd80
AU2021388021A1 (en) 2020-11-24 2023-06-22 Novartis Ag Anti-cd48 antibodies, antibody drug conjugates, and uses thereof
AU2021385349A1 (en) 2020-11-24 2023-06-22 Les Laboratoires Servier Mcl-1 inhibitor antibody-drug conjugates and methods of use
EP4288434A1 (en) 2021-02-02 2023-12-13 Les Laboratoires Servier Selective bcl-xl protac compounds and methods of use
WO2023225336A1 (en) 2022-05-20 2023-11-23 Novartis Ag Met bcl-xl inhibitor antibody-drug conjugates and methods of use thereof
WO2023225320A1 (en) 2022-05-20 2023-11-23 Novartis Ag Epha2 bcl-xl inhibitor antibody-drug conjugates and methods of use thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2714880A1 (de) * 1977-04-02 1978-10-26 Hoechst Ag Cephemderivate und verfahren zu ihrer herstellung
JPS59141547A (ja) * 1983-02-01 1984-08-14 Eisai Co Ltd 鎮痛作用を有する新規ペプタイドおよび製法
FR2575753B1 (fr) * 1985-01-07 1987-02-20 Adir Nouveaux derives peptidiques a structure polycyclique azotee, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
DK167813B1 (da) * 1989-12-07 1993-12-20 Carlbiotech Ltd As Pentapeptidderivat, farmaceutisk acceptable salte heraf, fremgangsmaade til fremstilling deraf og farmaceutisk praeparat indeholdende et saadant derivat
US5559209A (en) * 1993-02-18 1996-09-24 The General Hospital Corporation Regulator regions of G proteins
US6472172B1 (en) * 1998-07-31 2002-10-29 Schering Aktiengesellschaft DNA encoding a novel human inhibitor-of-apoptosis protein
PE20020058A1 (es) 2000-05-23 2002-01-31 Vertex Pharma Derivados de piperidina tetrahidroquinolina, tetrahidroisoquinolina como inhibidores de caspasas
US6608026B1 (en) * 2000-08-23 2003-08-19 Board Of Regents, The University Of Texas System Apoptotic compounds
US20020160975A1 (en) * 2001-02-08 2002-10-31 Thomas Jefferson University Conserved XIAP-interaction motif in caspase-9 and Smac/DIABLO for mediating apoptosis
WO2003040172A2 (en) * 2001-11-09 2003-05-15 Aegera Therapeutics, Inc. Methods and reagents for peptide-bir interaction screens
WO2004005248A1 (en) 2002-07-02 2004-01-15 Novartis Ag Peptide inhibitors of smac protein binding to inhibitor of apoptosis proteins (iap)
AU2003265276A1 (en) * 2002-07-15 2004-02-02 The Trustees Of Princeton University Iap binding compounds
US20040171554A1 (en) * 2003-02-07 2004-09-02 Genentech, Inc. Compositions and methods for enhancing apoptosis
US7067274B2 (en) * 2003-11-13 2006-06-27 Genentech, Inc. Compositions and methods for the screening pro-apoptotic compounds
CN1933847A (zh) * 2004-01-16 2007-03-21 密歇根大学董事会 Smac肽模拟物及其应用
SE527038C2 (sv) * 2004-02-26 2005-12-13 Ingenjoers N Per Oskar Persson Kassett och apparat för vätskefrysning
CN1926118A (zh) * 2004-03-01 2007-03-07 德克萨斯大学董事会 二聚的小分子细胞凋亡增强剂
ME02125B (me) 2004-04-07 2013-04-30 Novartis Ag Inhibitori protein apoptoze (iap)
CN101035802A (zh) 2004-07-02 2007-09-12 健泰科生物技术公司 Iap抑制剂
EA019420B1 (ru) * 2004-12-20 2014-03-31 Дженентех, Инк. Пирролидиновые ингибиторы иап (ингибиторов апоптоза)
US20060218632A1 (en) * 2005-03-28 2006-09-28 Cisco Technology, Inc.; Method and system for installing premise equipment
RU2009117701A (ru) * 2006-10-12 2010-11-20 Новартис АГ (CH) Производные пирролидина в качестве ингибиторов iap
CA2670728A1 (en) * 2006-12-07 2008-06-19 Novartis Ag Pyridine derivatives used as xiap inhibitors

Also Published As

Publication number Publication date
EP2051990B1 (en) 2013-02-06
WO2008016893A1 (en) 2008-02-07
NO342230B1 (no) 2018-04-23
TN2009000034A1 (en) 2010-08-19
CU20090017A7 (es) 2011-03-21
EA201401247A1 (ru) 2015-07-30
PE20110220A1 (es) 2011-04-11
KR20090038479A (ko) 2009-04-20
AR110313A2 (es) 2019-03-13
ES2559042T3 (es) 2016-02-10
EA021671B1 (ru) 2015-08-31
SMP200900013B (it) 2010-01-19
US8546336B2 (en) 2013-10-01
CA2658525A1 (en) 2008-02-07
MY150460A (en) 2014-01-30
IL196596A (en) 2014-09-30
IL196596A0 (en) 2009-11-18
ES2405947T3 (es) 2013-06-04
MA30652B1 (fr) 2009-08-03
NO20090878L (no) 2009-04-27
HRP20130373T1 (en) 2013-05-31
PE20080951A1 (es) 2008-09-11
CA2658525C (en) 2013-02-19
KR101245945B1 (ko) 2013-03-22
KR20110030667A (ko) 2011-03-23
AR062159A1 (es) 2008-10-22
CU20110027A7 (es) 2011-12-28
CN101511860B (zh) 2013-05-01
CN102558165A (zh) 2012-07-11
CN102558165B (zh) 2014-08-13
CN101511860A (zh) 2009-08-19
PA8740901A1 (es) 2009-04-23
HN2009000214A (es) 2011-10-11
EP2051990A1 (en) 2009-04-29
CR10567A (es) 2009-02-18
NI200900081A (es) 2010-01-07
DOP2013000084A (es) 2013-06-15
EP2537846B1 (en) 2015-09-16
EP2537850A1 (en) 2012-12-26
CL2007002234A1 (es) 2008-06-13
UA95485C2 (uk) 2011-08-10
IL236883A0 (en) 2015-03-31
JP4875749B2 (ja) 2012-02-15
BRPI0714803B1 (pt) 2021-03-09
ME00585B (me) 2011-12-20
GT200900019A (es) 2010-06-01
BRPI0714803A2 (pt) 2013-05-21
DK2051990T3 (da) 2013-05-13
CU23866B1 (es) 2013-03-27
NZ574393A (en) 2012-03-30
US20110065726A1 (en) 2011-03-17
CR20140555A (es) 2015-01-14
MX2009001212A (es) 2009-02-11
AU2007281230B2 (en) 2011-09-08
ZA200900371B (en) 2009-12-30
AR112816A2 (es) 2019-12-18
PE20110224A1 (es) 2011-04-05
GEP20115251B (en) 2011-07-11
HK1176613A1 (en) 2013-08-02
US8552003B2 (en) 2013-10-08
SV2009003160A (es) 2010-04-13
GT200900019AA (es) 2015-11-24
TWI408133B (zh) 2013-09-11
HK1127616A1 (en) 2009-10-02
CU24004B1 (es) 2014-06-27
EP2537846A1 (en) 2012-12-26
JO2848B1 (en) 2014-09-15
NI200900008A (es) 2010-01-07
IL231079A (en) 2015-02-26
EA200900227A1 (ru) 2009-08-28
PE20110217A1 (es) 2011-04-01
IL231079A0 (en) 2014-03-31
US20130005663A1 (en) 2013-01-03
TW200815399A (en) 2008-04-01
KR101087878B1 (ko) 2011-11-30
PT2051990E (pt) 2013-05-10
US20140004101A1 (en) 2014-01-02
ME00585A (en) 2011-12-20
SI2051990T1 (sl) 2013-06-28
PE20110218A1 (es) 2011-04-01
SMAP200900013A (it) 2009-05-11
PL2051990T3 (pl) 2013-07-31
AU2007281230A1 (en) 2008-02-07
JP2009545613A (ja) 2009-12-24

Similar Documents

Publication Publication Date Title
BRPI0714803B8 (pt) compostos peptidomiméticos de smac, seus usos, e composição farmacêutica
BR112015029512A8 (pt) derivados de pirazolopirrolidina, seus usos, e composição e combinação farmacêuticas
BRPI0618479A2 (pt) pirrolpiridinas composição farmacêutica que as contém
UY30559A1 (es) Derivados de morfolino pirimidina, procesos de preparacion, composiciones conteniéndolos y aplicaciones
BR112012029405A8 (pt) compostos macrocíclicos como inibidores de trk quinase
BRPI0906444A8 (pt) compostos de 4-piridinona e seu uso para câncer
BR112013004368A2 (pt) compostos tendo a fórmula geral (i) e composição farmacêutica
CO6390066A2 (es) Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas
BR112015029491A2 (pt) derivados de imidazopirrolidinona e seu uso no tratamento de doença
BR112012003578A8 (pt) Composto, sal farmaceuticamente aceitável, sal de sulfato, composição farmacêutica, método para tratar uma infecção viral, e, uso de um composto ou sal
CO6251364A2 (es) Derivados de morfolino pirimidina utilazdos en enfermedades relacionados con mtor quinasa y/o p13k
BR112015003188A2 (pt) Composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente
UY30759A1 (es) Compuestos quimicos
BR112015014458A8 (pt) compostos derivados de manose, seus intermediários, composição, uso e processos de preparação
BRPI0810064B8 (pt) compostos contendo nitrogênio tricíclico como agentes antibacterianos, composições farmacêuticas que compreendem os ditos compostos e uso dos mesmos para o tratamento de infecções bacterianas em mamíferos
NI201000003A (es) Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas.
UY32302A (es) Carboxamidas heterobicíclicas como inhibidoras de cinasas
BR122014013631B8 (pt) compostos antivirais, seu uso e composição farmacêutica compreendendo os mesmos
SV2009003299A (es) Derivados de dihidropiridina de utilidad como inhibidores de la proteina quinasa
BRPI0916286B8 (pt) amidofenóxi-indazóis úteis como inibidores de c-met, seus usos, e composição farmacêutica
BRPI1011838B8 (pt) compostos de carboxamida heterocíclica de diamino, seu uso, composição farmacêutica que os compreende e inibidor contra a atividade de cinase de proteína de fusão eml4-alk
BRPI0915064B8 (pt) derivados de quinoxalinadiona, seus usos, e medicamentos
BRPI0519424B8 (pt) compostos, composição e uso dos ditos compostos para a preparação de um medicamento para prevenção ou tratamento de um distúrbio de proliferação celular ou infecção microbiana
BR112015029401A8 (pt) derivados de pirazolo-pirrolidin-4-ona, seus usos, e composição e combinação farmacêuticas
BRPI0806863B8 (pt) uso de um éster de forbol na preparação de um medicamento para prevenção ou tratamento de uma infecção por hiv

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 09/03/2021, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 31/07/2007 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF